| BASILEA N |
| 日期/时间 | / |
| 涨跌。 / 涨跌。(%) | - / |
| Bid | - |
| Ask | - |
| 打开 | - |
| 以往收市 | - |
| 高 | - |
| 低 | - |
| 成交量 [CHF] | - |
| 成交量 [Units] | |
| Price fixings | |
| ISIN | CH0011432447 |
| 符号 | BSLN |
| 交易所 | SIX Swiss Exchange |
| 类型 | 股票 |
所有交易
| 交易所 | 最后的 | 成交量 | |
|---|---|---|---|
| Lang & Schwa.. | 32,75 |  |
|
| SIX Swiss Ex.. | 33,700 |  |
19.445 |
| London Domes.. | 34,00 | |
3.671 |
| Cboe Europe .. | 33,70 | |
554 |
| Cboe Europe .. | 33,70 | |
459 |
| Turquoise | 33,85 | |
294 |
| Nasdaq Other.. | 41,0000 | 40 | |
| München | 32,300 | 0 | |
| Berlin | 32,100 | 0 | |
| Frankfurt | 32,2800 | 0 | |
| gettex | 32,340 | ||
| TradeGate | 30,300 | 33 | |
| EUREX | Options | ||
新闻
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
08.03.2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
15.02.2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
24.01.2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
13.01.2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
11.01.2022 / 07:15 - GlobeNewswire